The recent call for the eradication of malaria has sparked the development of new drug classes with improved product profiles. Wells and colleagues review the currently available antimalarials and their limitations, the contribution of genome-based technologies andin vitroscreening of whole parasites to the discovery of new targets, and the issues that should be considered when developing such antimalarials.
- Timothy N. C. Wells
- Pedro L. Alonso
- Winston E. Gutteridge
